| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by financing activities | 17,119 | 7,639 |
| Effect of exchange rate changes on cash | 6 | 6 |
| Net increase (decrease) in cash and restricted cash | 785 | -4,430 |
| Cash and cash equivalents at beginning of period | 9,809 | - |
| Cash and cash equivalents at end of period | 10,594 | - |
Calidi Biotherapeutics, Inc. (CLDWW)
Calidi Biotherapeutics, Inc. (CLDWW)